Welcome to our dedicated page for Eikon Therapeutics SEC filings (Ticker: EIKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eikon Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eikon Therapeutics's regulatory disclosures and financial reporting.
Eikon Therapeutics, Inc. insider Roger M. Perlmutter, the company’s Chief Executive Officer and Director, indirectly acquired 284,857 shares of common stock on February 6, 2026 through derivative conversions tied to the company’s initial public offering.
Series A-1 Preferred Stock representing 1,268,891 shares and Series D Preferred Stock representing 855,512 shares each converted into common stock immediately prior to the IPO closing on a 1-for-7.4578 basis. The resulting common shares are held indirectly for Perlmutter’s benefit through Perlmutter Consulting, Inc., in which he had the sole pecuniary interest.
Entities affiliated with The Column Group reported sizable ownership changes in Eikon Therapeutics, Inc. (EIKN) tied to the company’s initial public offering. On February 6, 2026, multiple funds converted preferred stock into common and also bought additional shares.
The Column Group IV, LP, IV-A, LP and Opportunity III, LP converted Series A, A-1, C-1 and D preferred shares into common stock at an approximate 0.1340878-to-1 ratio and now hold indirect positions including 4,312,139, 148,840 and 1,319,164 common shares, respectively. On the same date, these entities also made open-market purchases of 1,437,323, 49,556 and 630,881 common shares at $18 per share. The filing states that the reporting persons disclaim beneficial ownership beyond their pecuniary interest.
Foresite Capital Management IV, LLC reported multiple insider transaction types in a Form 4 filing for EIKN. The filing lists transactions totaling 34,239,351 shares at a weighted average price of $18.00 per share. Following the reported transactions, holdings were 1,943,682 shares.
Eikon Therapeutics director Kenneth C. Frazier bought 111,111 shares of the company’s common stock in an open-market transaction. The purchase took place on February 4, 2026 at a price of $18 per share, and he now directly holds 111,111 shares.
Lux-affiliated investment funds associated with Eikon Therapeutics director and 10% owner Josh Wolfe reported significant share activity around the company’s IPO. On February 4, 2026, Lux Co-Invest Opportunities II and Lux Total Opportunities each bought 138,888 Eikon common shares in open-market transactions at $18 per share, held indirectly through their general partners.
On February 6, 2026, multiple series of Lux-held preferred stock automatically converted into Eikon common stock immediately prior to the IPO at a 1-for-7.4578 conversion rate. This resulted in indirect common stock positions including 2,387,705 shares held for Lux Ventures V, 1,290,428 shares held for a Lux Co-Invest vehicle, and 2,294,653 shares held for a Lux Total Opportunities fund. Voting and dispositive power is exercised by Lux general partner entities; Wolfe and Peter Hebert may be deemed beneficial owners through those entities, while each disclaims beneficial ownership beyond their pecuniary interest.
Eikon Therapeutics, Inc. reported insider transactions by Lux-affiliated investment entities related to its IPO. On February 4, 2026, Lux Co-Invest Opportunities II, L.P. and Lux Total Opportunities, L.P. each indirectly bought 138,888 shares of common stock at $18 per share in open-market purchases.
On February 6, 2026, several Lux funds indirectly acquired common stock through conversions of preferred stock, including 10,000,000 shares of Series A Preferred Stock and multiple series of A-1, B, B-1, C, C-1 and D Preferred Stock. These preferred shares converted into common stock immediately prior to the closing of Eikon’s initial public offering on a 1-for-7.4578 basis. The Lux entities report indirect beneficial ownership, and the managing members, including director Josh Wolfe and Peter Hebert, disclaim beneficial ownership except to the extent of their pecuniary interests.
Eikon Therapeutics, Inc. reported that, in connection with the closing of its initial public offering on February 6, 2026, it put in place a new legal and governance framework. Immediately prior to the IPO closing, the company’s board and stockholders approved an amended and restated certificate of incorporation and amended and restated bylaws.
The restated certificate of incorporation was filed with the Delaware Secretary of State, and the updated bylaws became effective on February 6, 2026. These documents define the company’s capital structure and core governance rules as a newly public company whose common stock trades on the Nasdaq Stock Market under the symbol EIKN.
Eikon Therapeutics, Inc. is conducting an initial public offering of 21,177,600 shares of common stock at $18.00 per share, for a stated gross offering amount of $381,196,800 and estimated net proceeds to the company, before expenses, of $354,513,024. Underwriters have a 30‑day option to buy up to 3,176,640 additional shares at the same price, less underwriting discounts and commissions. The stock is approved for listing on the Nasdaq Global Select Market under the symbol “EIKN.”
Eikon is a late‑stage clinical biopharmaceutical company focused on oncology, with multiple product candidates in Phase 1/2 and Phase 2/3 trials, including toll‑like receptor and selective PARP1 inhibitors, a WRN helicase inhibitor, and androgen receptor programs. The company estimates cash, cash equivalents and short‑term investments of approximately $336.0 million as of December 31, 2025, but has reported recurring net losses of about $244.6 million for the nine months ended September 30, 2025 and an accumulated deficit of $840.9 million. Its own analysis notes substantial doubt about its ability to continue as a going concern without raising additional capital.